in improving hair growth in women with thinning hair in the
menopausal transition.
CONCLUSION
The results of this 12-month study demonstrate that continued
use of a novel nutraceutical provides significant incremental
improvement over the beneficial effects achieved during
the initial 6-month randomized, placebo-controlled phase.
Continuous use may provide ongoing improvements in hair
growth and exert a positive effect on secondary symptoms
of menopause, as well as quality of life. There were no
unanticipated adverse events reported and the supplement was
well-tolerated over the year-long study duration.
DISCLOSURES
Drs Kogan and Raymond are employees of Nutraceutical
Wellness, LLC, New York, NY. Dr Ablon has nothing to disclose.
The study was conducted with a grant from Nutraceutical
Wellness LLC, New York, NY.
ACKNOWLEDGMENT
Drs. Kogan and Raymond are employees of Nutraceutical
Wellness, LLC, New York, NY. Dr. Ablon has nothing to disclose.
The study was conducted with a grant from Nutraceutical
Wellness, LLC, New York, NY. The authors acknowledge the
editorial assistance of Dr. Carl S. Hornfeldt, Apothekon, Inc.,
during the preparation of this manuscript.
REFERENCES
1. Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. An Bras Dermatol. 2015;90(4):529-543.
2. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184-189.
3. Schmitt JV, Ribeiro CF, Souza FH, et al. Hair loss perception and symptoms of depression in female outpatients attending a general dermatology clinic. An Bras Dermatol. 2012;87(3):412-417.
4. Sadick NS, Callender VD, Kircik LH, Kogan S. New insight into the pathophysiology of hair loss trigger a paradigm shift in the treatment approach. J Drugs Dermatol. 2017;16(11):s135-s140.
5. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558-565.
6. Rose PT. Combination approaches for combatting hair loss. Dermatol Clin. 2021;39(3):479-485.
7. Davis DS, Callender VD. Review of quality of life studies in women with alopecia. Int J Womens Dermatol. 2018;4(1):18-22. Published 2018 Jan 9.
8. Starace M, Orlando G, Alessandrini A, Piraccini BM. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020;21(1):69-84.
9. Titeca G, Goudetsidis L, Francq B, et al. The psychosocial burden of alopecia areata and androgenetica: a cross-sectional multicentre study among dermatological out-patients in 13 European countries. [published correction appears in J Eur Acad Dermatol Venereol. 2020 May;34(5):1119]. J Eur Acad Dermatol Venereol. 2020;34(2):406-411.
10. Bienenfeld A, Azarchi S, Lo Sicco K, et al. Androgens in women: androgenmediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497-1506.
11. Ali I, Wojnarowska F. Physiological changes in scalp, facial and body hair after the menopause: a cross-sectional population-based study of subjective changes. Br J Dermatol. 2011;164(3):508-513.
12. Mirmirani P. Hormonal changes in menopause: do they contribute to a 'midlife hair crisis' in women? Br J Dermatol. 2011;165 Suppl 3:7-11.
13. Ahluwalia J, Fabi SG. The psychological and aesthetic impact of age-related hair changes in females. J Cosmet Dermatol. 2019;18(4):1161-1169.
14. Ablon G. Nutraceuticals. Dermatol Clin. 2021;39(3):417-427.
15. Farris PK, Rogers N, McMichael A, Kogan S. A novel multi-targeting approach to treating hair loss, using standardized nutraceuticals. J Drugs Dermatol. 2017;16(11):s141-s148.
16. Ablon G, Kogan S. A randomized, double-blind, placebo-controlled study of a nutraceutical supplement for promoting hair growth in perimenopausal, menopausal, and postmenopausal women with thinning hair. J Drugs Dermatol. 2021;20(1):55-61.
17. Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003;1:28. Published 2003 Jul 30.
18. Dolte KS, Girman CJ, Hartmaier S, et al. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol. 2000;25(8):637-642.
19. Thom E. Stress and the hair growth cycle: cortisol-induced hair growth disruption. J Drugs Dermatol. 2016;15(8):1001-1004.
20. Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID-19 emergency: psychological implications. Dermatol Ther. 2020;33(4):e13648.
21. Turkmen D, Altunisik N, Sener S, Colak C. Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire. Dermatol Ther. 2020;33(6):e13923.
22. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558-565.
23. Auddy B, et al. A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study. J Am Nutraceut Ass. 2008;11(1):50-56.
24. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. [published correction appears in J Altern Complement Med. 2006 Mar;12(2):199]. J Altern Complement Med. 2002;8(2):143-152.
25. Rossi A, Mari E, Scarno M, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167-1173.
26. Buonocore D, Verri M, Cattaneo L, et al. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for benign prostatic hyperplasia. Arch Ital Urol Androl. 2018;90(3):199-202. Published 2018 Sep 30.
27. Cheng C, Shen F, Ding G et al. Lepidiline A improves the balance of endogenous sex hormones and increases fecundity by targeting HSD17B1. Mol Nutr Food Res. 2020;64(10):e1900706.
28. Meissner HO, Reich-Bilinska H, Mscisz A, Kedzia B. Therapeutic effects of pre-gelatinized maca (Lepidium peruvianum chacon) used as a non-hormonal alternative to HRT in perimenopausal women - clinical pilot study. Int J Biomed Sci. 2006;2(2):143-159.
29. López-Fando A, Gómez-Serranillos MP, Iglesias I, et al. Lepidium peruvianum chacon restores homeostasis impaired by restraint stress. Phytother Res. 2004;18(6):471-474.
30. Zou Y, Aboshora W, Li J, et al. Protective effects of Lepidium meyenii (maca) aqueous extract and lycopene on testosterone propionate-induced prostatic hyperplasia in mice. Phytother Res. 2017;31(8):1192-1198.
31. Akazawa N, Choi Y, Miyaki A, et al. Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr Res. 2012;32(10):795-799.
32. Sztretye M, Dienes B, Gönczi M, et al. Astaxanthin: a potential mitochondrialtargeted antioxidant treatment in diseases and with aging. Oxid Med Cell Longev. 2019;2019:3849692. Published 2019 Nov 11.
33. Woods NF, Mitchell ES, Smith-Dijulio K. Cortisol levels during the menopausal transition and early post-menopause: observations from the Seattle Midlife Women's Health Study. Menopause. 2009;16(4):708-718.
34. Gava G, Orsili I, Alvisi S, et al. Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. Medicina (Kaunas). 2019;55(10):668. Published 2019 Oct 1.
2. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184-189.
3. Schmitt JV, Ribeiro CF, Souza FH, et al. Hair loss perception and symptoms of depression in female outpatients attending a general dermatology clinic. An Bras Dermatol. 2012;87(3):412-417.
4. Sadick NS, Callender VD, Kircik LH, Kogan S. New insight into the pathophysiology of hair loss trigger a paradigm shift in the treatment approach. J Drugs Dermatol. 2017;16(11):s135-s140.
5. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558-565.
6. Rose PT. Combination approaches for combatting hair loss. Dermatol Clin. 2021;39(3):479-485.
7. Davis DS, Callender VD. Review of quality of life studies in women with alopecia. Int J Womens Dermatol. 2018;4(1):18-22. Published 2018 Jan 9.
8. Starace M, Orlando G, Alessandrini A, Piraccini BM. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020;21(1):69-84.
9. Titeca G, Goudetsidis L, Francq B, et al. The psychosocial burden of alopecia areata and androgenetica: a cross-sectional multicentre study among dermatological out-patients in 13 European countries. [published correction appears in J Eur Acad Dermatol Venereol. 2020 May;34(5):1119]. J Eur Acad Dermatol Venereol. 2020;34(2):406-411.
10. Bienenfeld A, Azarchi S, Lo Sicco K, et al. Androgens in women: androgenmediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497-1506.
11. Ali I, Wojnarowska F. Physiological changes in scalp, facial and body hair after the menopause: a cross-sectional population-based study of subjective changes. Br J Dermatol. 2011;164(3):508-513.
12. Mirmirani P. Hormonal changes in menopause: do they contribute to a 'midlife hair crisis' in women? Br J Dermatol. 2011;165 Suppl 3:7-11.
13. Ahluwalia J, Fabi SG. The psychological and aesthetic impact of age-related hair changes in females. J Cosmet Dermatol. 2019;18(4):1161-1169.
14. Ablon G. Nutraceuticals. Dermatol Clin. 2021;39(3):417-427.
15. Farris PK, Rogers N, McMichael A, Kogan S. A novel multi-targeting approach to treating hair loss, using standardized nutraceuticals. J Drugs Dermatol. 2017;16(11):s141-s148.
16. Ablon G, Kogan S. A randomized, double-blind, placebo-controlled study of a nutraceutical supplement for promoting hair growth in perimenopausal, menopausal, and postmenopausal women with thinning hair. J Drugs Dermatol. 2021;20(1):55-61.
17. Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003;1:28. Published 2003 Jul 30.
18. Dolte KS, Girman CJ, Hartmaier S, et al. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol. 2000;25(8):637-642.
19. Thom E. Stress and the hair growth cycle: cortisol-induced hair growth disruption. J Drugs Dermatol. 2016;15(8):1001-1004.
20. Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID-19 emergency: psychological implications. Dermatol Ther. 2020;33(4):e13648.
21. Turkmen D, Altunisik N, Sener S, Colak C. Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire. Dermatol Ther. 2020;33(6):e13923.
22. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558-565.
23. Auddy B, et al. A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study. J Am Nutraceut Ass. 2008;11(1):50-56.
24. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. [published correction appears in J Altern Complement Med. 2006 Mar;12(2):199]. J Altern Complement Med. 2002;8(2):143-152.
25. Rossi A, Mari E, Scarno M, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167-1173.
26. Buonocore D, Verri M, Cattaneo L, et al. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for benign prostatic hyperplasia. Arch Ital Urol Androl. 2018;90(3):199-202. Published 2018 Sep 30.
27. Cheng C, Shen F, Ding G et al. Lepidiline A improves the balance of endogenous sex hormones and increases fecundity by targeting HSD17B1. Mol Nutr Food Res. 2020;64(10):e1900706.
28. Meissner HO, Reich-Bilinska H, Mscisz A, Kedzia B. Therapeutic effects of pre-gelatinized maca (Lepidium peruvianum chacon) used as a non-hormonal alternative to HRT in perimenopausal women - clinical pilot study. Int J Biomed Sci. 2006;2(2):143-159.
29. López-Fando A, Gómez-Serranillos MP, Iglesias I, et al. Lepidium peruvianum chacon restores homeostasis impaired by restraint stress. Phytother Res. 2004;18(6):471-474.
30. Zou Y, Aboshora W, Li J, et al. Protective effects of Lepidium meyenii (maca) aqueous extract and lycopene on testosterone propionate-induced prostatic hyperplasia in mice. Phytother Res. 2017;31(8):1192-1198.
31. Akazawa N, Choi Y, Miyaki A, et al. Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr Res. 2012;32(10):795-799.
32. Sztretye M, Dienes B, Gönczi M, et al. Astaxanthin: a potential mitochondrialtargeted antioxidant treatment in diseases and with aging. Oxid Med Cell Longev. 2019;2019:3849692. Published 2019 Nov 11.
33. Woods NF, Mitchell ES, Smith-Dijulio K. Cortisol levels during the menopausal transition and early post-menopause: observations from the Seattle Midlife Women's Health Study. Menopause. 2009;16(4):708-718.
34. Gava G, Orsili I, Alvisi S, et al. Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. Medicina (Kaunas). 2019;55(10):668. Published 2019 Oct 1.
AUTHOR CORRESPONDENCE
Isabelle Raymond PhD Isabelle@nutrafol.com
